The men’s health market is more interesting than you think.
The space is characterized by rapid growth and increasing relevance, as men and couples start to confront the many previously unexploited channels to improved intimacy, self-confidence, and overall well-being that men have traditionally ignored or brushed aside in their quest to maintain the public facade of the invincible self-reliant hero to their kids, spouses, and friends.
Yet, according to researchers, suicide is much higher among men than women.
According to a recent piece from the BBC, compared to women, men are three times more likely to die by suicide in Australia, 3.5 times more likely in the US and more than four times more likely in Russia and Argentina. WHO’s data show that nearly 40% of countries have more than 15 suicide deaths per 100,000 men; only 1.5% show a rate that high for women.
Any guess as to why?
Men aren’t supposed to cry; aren’t supposed to be vulnerable; aren’t supposed to reach out for help. Men are just supposed to figure it out and stay strong; to never show weakness; to find a solution on their own.
While this leads to a much higher incidence of male suicide, it also leads to other issues. One of the biggies is a lack of proactive health treatments, preventative care, or the seeking of solutions for things like erectile dysfunction, where taboos and stigma play a major role in preventing individuals from pursuing help.
But research and knowledge are apparently starting to pay off as culture increasingly bends toward supporting our dads, brothers, buddies, and sons when they reach out for help with something that demands expert assistance.
As a result, the men’s health market appears to be a boom in the making, with growth projected to power along at 15% per year for the next half decade.
That exponential growth curve is riding a wave driven by a variety of factors, including increased awareness of men’s health issues, a shift in societal norms encouraging men to prioritize self-care, and advancements in medical technology and research.
As the global focus on men’s health continues to gain momentum, the men’s health market emerges as a vital industry, poised to make a significant impact on the lives of men worldwide.
With that in mind, we take a look below at some of the most interesting stocks tethered to this emerging theme.
Teladoc Health Inc (NYSE:TDOC) isn’t straight on the money as a men’s health play, but it is clearly leveraged to the theme as it provides for ease of access to medical care through non-traditional pathways and emphasizes proactive healthcare through its telehealth platform and network of services – that format of proactive care has resonated well with male patients.
The company engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through its Teladoc Health Integrated Care, BetterHelp, and Others segments. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services.
Teladoc Health Inc (NYSE:TDOC) recently reported its first-quarter 2023 financial results, showcasing momentum in the face of challenges. The company’s adjusted loss per share of 37 cents exceeded expectations, reflecting a 21.3% improvement compared to the previous year. Operating revenues for the quarter reached $629.2 million. The strong performance of Teladoc was driven primarily by increases in access fees and other revenues, as well as improved profitability in the Integrated Care segment. Although there were some earnings declines in the BetterHelp segment, they were partially offset by the overall positive results.
Teladoc remains well-positioned in the rapidly evolving telehealth industry. The company’s ability to execute its strategic plans, capitalize on the growing demand for virtual healthcare services, and leverage its strong brand recognition and established customer base bode well for future growth. Teladoc’s ongoing efforts to expand memberships, increase visits, and enhance its service offerings further contribute to its long-term prospects. With an industry projected to witness significant growth, Teladoc stands out as a compelling investment opportunity in the telemedicine sector.
Even in light of this news, TDOC has had a rough past week of trading action, with shares sinking something like -4% in that time. That said, chart support is nearby, and we may be in the process of constructing a nice setup for some movement back the other way.
Teladoc Health Inc (NYSE:TDOC) CEO Jason Gorevic noted, “Teladoc Health delivered strong first quarter results across all key financial and operating metrics to start the year. With a strong financial position, we are able to fund and invest in innovations and a world-class team of medical professionals as we support leading employers, health plans, hospital systems, and governments around the world. We have solid momentum heading into the rest of the year as the market embraces Teladoc Health’s unified whole person care experience.”
Mangoceuticals Inc (NASDAQ: MGRX) is focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango.”
Mango is a prescription medication that must be approved by a physician. However, the company has apparently worked to streamline that side of things through its online telehealth system that connects patients to Mango’s network of medical providers, who are standing by to review and approve a prescription if medically appropriate. Mango also appears to have another advantage over the competition: it’s a rapidly dissolved tablet (RDT). It gets absorbed orally, so it takes effect sooner—like 10-15 minutes. And it lasts up to 36 hours. About the only thing going against MGRX right now is just that it has been flying under the radar. But recent events suggest this is starting to change.
Mangoceuticals Inc (NASDAQ:MGRX) just announced this morning that it has added serial technology entrepreneur and investor, Aaron Andrew, to its advisory board. On January 5, 2023, the Company established the Advisory Board and approved and adopted a charter to govern the Advisory Board. Pursuant to the Advisory Board Charter, the primary function of the Advisory Board is to assist the Board of Directors in its general oversight of the Company’s development of new business ventures and strategic planning.
Mr. Andrew will assist the Company with providing his guidance and expertise as it relates to both curating content designed for influencer and affiliate marketing, in addition to making key introductions to his vast influencer network across the United States. He represents the third addition to the Company’s Advisory Board. Other members include Dr. Brian Rudman, founder of Dallas-based wellness clinic chain, Formula Wellness, and Jarrett Boon, an original thought-leader and investor involved in LifeLock, Inc.
As far as breaking into the public eye and flying in full radar view, MGRX has been taking a number of significant steps, including launching a major viral video marketing campaign and ringing the Nasdaq closing bell on live TV.
Mangoceuticals Inc (NASDAQ:MGRX) CEO, Jacob Cohen, commented on the launch of the new viral ad campaign, “This campaign is expected to help to further position Mango in the ED market as a uniquely accessible resource which has the goal of helping normal men achieve greater fulfillment and self-confidence while avoiding brand association with social discomfort. We believe we have opened up a disruptive new lane in this rapidly growing $3.5 billion market. Peak performance is a good thing. Making your life better is a good thing. Cultural barriers to talking frankly about that pursuit are a bad thing. Yet, until Mango came along, that’s typically how this marketplace tacitly operated. We believe that was a blind spot and the Mango brand is attempting to carve out a new model. We believe that the ‘Some Things Are Better Hard’ viral digital campaign is a perfect vehicle to press our incipient branding advantage.”
Hims & Hers Health Inc (NYSE: HIMS) bills itself as the leading health and wellness platform on a mission to help the world feel great through the power of better health.
According to the company’s materials, “We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.”
Hims & Hers Health Inc (NYSE: HIMS) recently announced financial results for the first quarter ended March 31, 2023. “We are pleased with our outstanding performance in the first quarter, as our ability to deliver more personalized and accessible products and services is inspiring more customers to take better care of their health and well-being,” said Andrew Dudum, co-founder and CEO. “Our significant market opportunity, robust consumer demand and consistent execution across our four strategic pillars – trusted brand, leading technology, product innovation and clinical excellence – uniquely positions us as a trusted market leader.”
“Our resilient customer base and durable recurring revenue model is operating at a scale that enables us to generate high growth while generating incremental efficiencies,” said Yemi Okupe, CFO. “These dynamics enable us to unlock our market opportunity from a position of strength and we expect to continue delivering leading innovation and access to care to our customers to capitalize on our growth momentum while driving operational excellence.”
Even in light of this news, HIMS has had a rough past week of trading action, with shares sinking something like -17% in that time. That said, chart support is nearby, and we may be in the process of constructing a nice setup for some movement back the other way.
Hims & Hers Health Inc (NYSE: HIMS) managed to rope in revenues totaling $190.8M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 88.3%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels exceeding current liabilities ($184.4M against $56.3M).
Other key players with ties to the Men’s Health space include Pfizer Inc. (NYSE: PFE), Creative Medical Technology Holdings Inc (NASDAQ: CELZ), Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), Goodrx Holdings Inc (NASDAQ:GDRX), and American Well Corp (NYSE:AMWL).
